Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955427 | 0.83 | HRH3 (0.49) | ALDH1A1FDPSKCNA5HRH3HRH1 | |
| SCHEMBL707791 | 0.82 | TSHR (0.47) | ALDH1A1FDPSKCNA5HPGDHSD17B10 | |
| SCHEMBL5010543 | 0.80 | PGK1 (0.52) | NPSR1HPGD | |
| SCHEMBL9111289 | 0.80 | TSHR (0.44) | ALDH1A1FDPSHRH3HRH1 | |
| SCHEMBL23801890 | 0.78 | NAMPT (0.38) | — | |
| SCHEMBL21518588 | 0.78 | ALDH1A1 (0.51) | ALDH1A1FDPSKCNA5HRH3HRH1 | |
| SCHEMBL8538608 | 0.78 | CTDSP1 (0.48) | NPSR1 | |
| SCHEMBL14260472 | 0.77 | CHRM2 (0.51) | ALDH1A1HPGDHSD17B10 | |
| Diethyl Hydrogen Phosphate SCHEMBL4953245 | 0.77 | FDPS (0.49) | ALDH1A1FDPSKCNA5HPGDHSD17B10 | |
| SCHEMBL3315956 | 0.77 | ALDH1A1 (0.48) | ALDH1A1NPSR1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022063784-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | US | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-10874646-B2 | Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof | WILLIAM MARSH RICE UNIVERSITY (US) | 2020-12-29 | — | — | US | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0646007-B1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5510351-A | PREGNANE ENZYME INHIBITOR FOR TREATING SKIN DISORDER, BALDNESS, PROSTATIC CANCER | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0646007-A4 | — | — | 1995-04-26 | — | — | EP | disclosed |
| EP-0646007-A1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-04-05 | — | — | EP | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993023050-A1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874646-B2 | Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof | EPOR, CD47, DHPS | ALDH1A1 117/4885FDPS 197/4885KCNA5 4770/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ALDH1A1 472/4885FDPS 1465/4885KCNA5 2071/4885 |
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | ALDH1A1 127/4885FDPS 1142/4885KCNA5 4769/4885 |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ALDH1A1 450/4885FDPS 1471/4885KCNA5 2018/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALDH1A1 450/4885FDPS 1471/4885KCNA5 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.